Carrying out intended dosing regimens often require highly concentrated protein formulations that may be too viscous for subcutaneous administration or other routes of administration that are limited by volume. While reducing viscosity with a single excipient can be ineffective or compromising protein stability, our platform featuring combinations of viscosity-reducing agents provides a variety of manufacturing and final formulation benefits.
Our Viscosity Reduction Platform enables subcutaneous formulation of highly concentrated protein biologics, bringing together increased concentrations and improved downstream processing.
Our offering comprises:
Proprietary new excipient combinations to enable your target concentration. Commercial use licenses are available. Commercial supply of excipients in Emprove® Expert quality to support your clinical development and commercialization Application know-how to support the selection of the most promising solution for your protein of interest
Your in-house screening (free-of-charge)
Feasibility testing service (fee-for-service)
Do you have a viscosity issue but no resources to test the platform? We offer support via our Feasibility Testing Service:
The result: subcutaneous administration of protein-based therapeutics to improve patient compliance and help avoid hospitalization.
|L-Arginine, EMPROVE® EXPERT, Ph. Eur., ChP, JP, USP
|Benzenesulfonic acid, EMPROVE® EXPERT
|L-Phenylalanine, EMPROVE® EXPERT Ph Eur,USP
|Thiamine phosphoric acid ester chloride dihydrate, EMPROVE® API
|Pyridoxine hydrochloride, EMPROVE® EXPERT, Ph. Eur., BP, JP, USP, FCC
|L-Ornithine monohydrochloride, EMPROVE® EXPERT, DAB